Jerry P. Abraham, MD, MPH, CMQ, discusses the persistent risks of COVID-19 and how a newly approved postexposure prophylaxis option is reshaping pharmacists' role in prevention.
Jerry P. Abraham, MD, MPH, CMQ
Advertisement
Articles by Jerry P. Abraham, MD, MPH, CMQ
Jerry P. Abraham, MD, MPH, CMQ, discusses why COVID-19 prevention strategies, including ensitrelvir for postexposure prophylaxis, remain essential for protecting vulnerable patients amid persistent summer transmission.
Ensitrelvir's 72-Hour Window: What Pharmacists Need to Know About COVID-19 PEP
Published: | Updated:
Jerry P. Abraham, MD, MPH, CMQ, discusses how ensitrelvir's new post-exposure prophylaxis indication gives pharmacists a critical 72-hour window to help prevent COVID-19 in high-risk patients.
Advertisement
Latest Updated Articles
Ensitrelvir's 72-Hour Window: What Pharmacists Need to Know About COVID-19 PEPPublished: August 4th 2026 | Updated: August 7th 2026
- Ensitrelvir's 72-Hour Window: What Pharmacists Need to Know About COVID-19 PEP
Published: August 4th 2026 | Updated: August 7th 2026
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
4
Baseline Interferon Activity in Monocytes Predicts mRNA Vaccine Adverse Effects, Study Finds
5